| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/14/2005 | US20050154033 Improve the safety anti-epilepsy therapy, reducing the side effect of drug, by informing and monitoring the patient by laboratory test, medical evaluation; adjusting the dosages |
| 07/14/2005 | US20050154032 Improve the safety anti-epilepsy therapy, reducing the side effect of drug, by informing and monitoring the patient by laboratory test, medical evaluation; adjusting the dosages |
| 07/14/2005 | US20050154031 which are selective against serotonin 5-HT2A and 5-HT2C receptors; 2-amino-5-methyl-4-(naphth-1-yl)thiazole; irritable bowel syndrome, dyspepsia, gastroesophageal reflux, tachygastria; migraine, neurogenic pain, anxiety, depression, sleep disorder, asthma, incontinence, endometriosis, and fibrosis |
| 07/14/2005 | US20050154030 Antimicrobial composition |
| 07/14/2005 | US20050154029 Identifying nicotinic acid receptor modulators for treatment and prevention of dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance and diabetes |
| 07/14/2005 | US20050154028 1-(3-Fluoro-phenyl)-3-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-imidazolidin-2-one; serotonin 5-ht2c receptor antagonist; antidepressant and anxiolytic agent |
| 07/14/2005 | US20050154026 Suitable for the treatment of gastric and intestinal disorders; in particular, omeprazole, rabeprazole, pantoprazole, esomeprazole |
| 07/14/2005 | US20050154025 6-[4-(fluoro- or trifluoromethyl)pyridyl-4-(p-fluorophenyl)-5-methylimidazol-2-yl] pyridones; cyclization of 1-phenyl-1-pyridyl-1,2-diaminopropanes with an acid, amidine, or nitrile compound; neuropeptide Y receptor antagonists; cardiovascular and central nervous system disorders, metabolic diseases |
| 07/14/2005 | US20050154024 Compounds useful in therapy |
| 07/14/2005 | US20050154023 1-(4-methoxynaphthalene-1-sulfonyl)-2,3-dihydro-1H-indole-3-carboxylic acid [2-(1-methyl-pyrrolidin-2-yl)-ethyl]amide; selective affinity for 5-HT6 receptor; psychosis, schizophrenia, depression, neurological disorders, cognitive enhancement, Parkinson's disease, ALS, Alzheimer's, Huntington's disease |
| 07/14/2005 | US20050154019 Substituted cyclic amine metalloprotease inhibitors |
| 07/14/2005 | US20050154018 Method for treating and preventing disorders using optically pure (+) norcisapride |
| 07/14/2005 | US20050154017 Novel azasugar derivative and drug containing the same as the active ingredient |
| 07/14/2005 | US20050154016 Preventives for hiv infection |
| 07/14/2005 | US20050154015 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 07/14/2005 | US20050154014 Anticarcinogenic agents; antitumor agents treating cancer of breast, head, neck, gastrointestinal system or stomach, ovaries, bronchi, lungs or pancreas; leukemia |
| 07/14/2005 | US20050154013 Pressurised metered dose inhalers containing solutions of beta-2 agonists |
| 07/14/2005 | US20050154012 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 07/14/2005 | US20050154010 Solid tumors; hematological or hemopoietic cancer; Halogen or trifluoromethyl-substituted 4-quinolinemethanols |
| 07/14/2005 | US20050154009 For example, (1R,2R,3S)-2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-3-(4-fluorophenyl)-tropane; use in treatment of neurodegenerative disorder with an associated cognitive deficit, such as Alzheimer's Disease, Lewis body disease, fronto-temporal dementia |
| 07/14/2005 | US20050154007 Substituted imidazo[1,2-a]pyridines such as 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-6-methoxyimidazo[1,2-a]pyridine, used as antisectory agents for prophylaxis of gastrointestinal disorders |
| 07/14/2005 | US20050154006 mixture of anticholinergic agents and pyridinecarboxamide's such as 2-(4-fluoro-phenoxy)-N-{4-(1-hydroxy-1-methyl-ethyl)-benzyl}nicotinamide in the form of enantiomers, racemates, solvates or hydrates and optionally mixed with excipients, used for treating respiratory system disorders |
| 07/14/2005 | US20050154005 Administering to a subject in need of such treatment an effective amount of 1,1'-[1,4-(phenylenebis(methylene))]bis-1,4,8,11-tetraazacyclotetradecane or a pharmaceutical composition thereof, wherein the inhibition of CXCR4 receptor binding effects treatment or amelioration of said condition |
| 07/14/2005 | US20050154004 4-Phenyl-6H-(1)Benzopyrano(4',3':4,5)pyrrolo(2,1-a)isoquinolin-6-one's and analogues, optionally mixed with acceptable carriers, excipients or diluents, used for treating multidrug resistant tumors, for inducing apoptosis and as immunology modulators |
| 07/14/2005 | US20050154003 Containing a 1H,3H-furo[3',4':6,7]indolizino[1,2-b]quinoline ring, e.g., {10-[(E)-(ter-butoxyimino)methyl]-3-ethyl-1,13-dioxo-11,13-dihydro-1H,3H-furo[3',4':6,7]indolizino[1,2-b]quinolin-3-yl}acetic acid; topoisomerase I inhibitors used to treat cancer |
| 07/14/2005 | US20050154002 Novel oral bioavailable prodrugs |
| 07/14/2005 | US20050154000 Diaza-spiropiperidine derivatives |
| 07/14/2005 | US20050153999 Pharmaceutical compositions |
| 07/14/2005 | US20050153998 Tetrahydroisoquinoline or isochroman compounds |
| 07/14/2005 | US20050153997 Fredericamycin derivatives |
| 07/14/2005 | US20050153996 Compounds that modulate ppar activity and methods for their preparation |
| 07/14/2005 | US20050153995 Nonnucleoside inhibitors of reverse transcriptase, composite binding pocket and methods for use thereof |
| 07/14/2005 | US20050153994 The use of 5-fluorourcil, delivered by iontophoresis as an inhibitor of cell proliferation in the eye, bulbar and palpebral conjunctiva, eyelid, peri-orbital soft tissues and skin |
| 07/14/2005 | US20050153993 Treatment of statin side effects using uridine derivatives |
| 07/14/2005 | US20050153992 Glycogen synthase kinase-3 inhibitors; pyrrolo[3,2-d]pyrimidine: neurodegenerative diseases; antidiabetic, antiinflammatory, anticancer agents; 5-(2-aminoethyl)-6-(3-chloro(2-thienyl))-7-iodo-3-hydropyrrolo[3,2-d]pyrimidin-4-thione Trifluoroacetate; 4-halo intermediates |
| 07/14/2005 | US20050153991 Methods of treatment of chronic lymphocytic leukemia using roscovitine |
| 07/14/2005 | US20050153990 Phosphonate substituted kinase inhibitors |
| 07/14/2005 | US20050153989 Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| 07/14/2005 | US20050153988 Novel polymorph of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto |
| 07/14/2005 | US20050153987 Compounds |
| 07/14/2005 | US20050153986 Psychiatric and mood disorders, Bipolar Disorder, Circadian rhythm disorders, sleep disorders, pain, Parkinson's disease, cognitive dysfunction, epilepsy, obesity, drug addiction, drug abuse, drug withdrawal; side effects reduction; 1-Methyl-3-[3-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]imidazolidin-2-one |
| 07/14/2005 | US20050153985 Methods of treating acute inflammation in animals with p38 map kinase inhibitors |
| 07/14/2005 | US20050153984 4-[5-(4-trifluoromethyl-phenyl)-pyridin-3-yloxy]-benzothiazol-2-ylamine; inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis |
| 07/14/2005 | US20050153983 Synergistic combination of an opioid analgesic and a nsaid |
| 07/14/2005 | US20050153982 Sustained release ranolazine formulations |
| 07/14/2005 | US20050153981 N1-phenacyl-N4-[2-(benzylamino)-2-oxo-ethyl] piperazine; as neuroprotective agents, in the treatment of ischemic cerebral apoplexy, human cerebral infraction; antiischemic agents for brain disorders; side effect reduction |
| 07/14/2005 | US20050153980 Substituted indoles |
| 07/14/2005 | US20050153979 Novel piperidine-substituted indoles-or heteroderivatives thereof |
| 07/14/2005 | US20050153978 Medicaments |
| 07/14/2005 | US20050153977 N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]-3-fluoro-4-hydroxybenzamide; nonpeptide c-mpl ligand; low immunogenicity; proliferate human c-mpl-Ba/F3 cells; increase platelets by promoting the formation of megakaryocytic colonies; orally |
| 07/14/2005 | US20050153976 1-[(1-acetyl-4-piperidinyl)acetyl]-2(S)-(1,1-dimethylethyl)-4(S)*4-[phenyl [4(trifluoromethoxy)phenyl]methyl]piperazine; hydrophobic inhibitors of Type 3 17 beta -Hydroxysteroid Dehydrogenase and hydrophilic carrier; solubilizing drug; less toxicity and precipitation; stability over time |
| 07/14/2005 | US20050153975 Y823D, N822K or D816H mutations in the c-Kit tyrosine kinase; antitumour agent; alternative to radiation or chemotherapy; reduce consequent infertility; good tolerability of compound mesylate treatment; no drug-related liver, renal or cardiac toxicity |
| 07/14/2005 | US20050153974 Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors |
| 07/14/2005 | US20050153973 (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes |
| 07/14/2005 | US20050153971 Halogenated biaryl heterocyclic compounds and methods of making and using the same |
| 07/14/2005 | US20050153970 N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity |
| 07/14/2005 | US20050153969 Inhibitors of DNA biosynthesis |
| 07/14/2005 | US20050153968 Monocyclic N-aryl hydantoin modulators of androgen receptor function |
| 07/14/2005 | US20050153967 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form |
| 07/14/2005 | US20050153966 2-hydroxy-1H-indol derivatives enzyme inhibitors for preventing or treating inflammation, inflammatory bowel disease, psoriasis, dementia related diseases Alzheimer's Disease, Cognitive Impairment, arthritis, neurodegenerative diseases, amyotrophic lateral sclerosis, Down syndrome, Huntington's Disease |
| 07/14/2005 | US20050153965 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| 07/14/2005 | US20050153964 Novel compounds |
| 07/14/2005 | US20050153963 exhibit a particular activity as specific inhibitors of the glycine transporters glyt1 and/or glyt2 |
| 07/14/2005 | US20050153961 to hypoxic tumor cells and aerobic cells following or preceding a hypoxic incubation of the cells with the drug; ability to kill hypoxic cells directly; in vitro and in vivo; substitution in position 3 determines desired activity for compound |
| 07/14/2005 | US20050153960 Substituted arylamine derivatives and methods of use |
| 07/14/2005 | US20050153957 Beta2-adrenoceptor agonists |
| 07/14/2005 | US20050153956 Pharmaceutical compositions comprising midazolam in a high concentration |
| 07/14/2005 | US20050153955 Compounds and compositions as protein kinase inhibitors |
| 07/14/2005 | US20050153954 Stirring polymorphic olanzapine in 1-butanol or tert-butanol; isolating solid; drying |
| 07/14/2005 | US20050153953 Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors |
| 07/14/2005 | US20050153952 Methods for inhibiting sterol absorption |
| 07/14/2005 | US20050153950 Broad -spectrum cephem compounds |
| 07/14/2005 | US20050153949 Testosterone derivative |
| 07/14/2005 | US20050153948 Methods and formulations for the treatment of medical conditions related to elevated dihydrotestosterone |
| 07/14/2005 | US20050153947 administering mixture of serotonine reuptake inhibitor and corticosteroid |
| 07/14/2005 | US20050153946 Water; antiinflammatory steroid and/or steroidal hormones, propylene glycol, polyethylene glycol, preservative,stabilizer; and buffer; concentration; seeding a crystal; forming heterogeneous mixture; heat resistance |
| 07/14/2005 | US20050153945 Small molecules and a pharmacophore model for inhibition of botulinum toxin and methods of making and using thereof |
| 07/14/2005 | US20050153944 Oxazole derivatives of tetracyclines |
| 07/14/2005 | US20050153943 Administering to mammal an effective amount of an anti-mucositis and anti-fungal pharmaceutical composition consisting of a tetracycline compound; no antibiotic activity |
| 07/14/2005 | US20050153942 Heterocyclic inhibitors of MEK and methods of use thereof |
| 07/14/2005 | US20050153941 Cell differntiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line |
| 07/14/2005 | US20050153940 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 07/14/2005 | US20050153939 Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts |
| 07/14/2005 | US20050153938 Polyphosphonate derivatives for toothpaste compositions |
| 07/14/2005 | US20050153937 Administering encapsulated liposome nanoparticles of alendronate, pamidronate, clondronate, etidronate, tiludronate, gold, gallium, gadolinium, and/or selenium; treating hypersensitivity and/or complement activation-related pseudoallergy (CARPA) |
| 07/14/2005 | US20050153936 Administering (1-phosphono- or 1-carboxymethyl)cyclopenylcarbonylamino-substituted benzazepinone, benzoxazepinone, or benzothiazepine-N-acetic acid derivative, e.g., 2R)-2-{[1-({[(3S)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}carbonyl)cyclopentyl]methyl}-4-phenylbutanoic acid |
| 07/14/2005 | US20050153934 Chaperone-based therapy for Niemann-Pick disease |
| 07/14/2005 | US20050153932 Controlled muscle relaxation |
| 07/14/2005 | US20050153931 Comprises cannabinol, tetrahydrocannabinol and cannabidiol; bioavailability |
| 07/14/2005 | US20050153930 Via gadolinium compounds as calcium channel blockers; drug screening |
| 07/14/2005 | US20050153929 E5564; antagonist of hydrophobic lipid A portion of Gram negative bacteria; endotoxemia, sepsis, or septic shock, HIV, immunological disorder, leukemia, graft-versus-host disease, bone marrow or stem cell transplant; bolus or intermittent intravenous infusion |
| 07/14/2005 | US20050153928 Conjugates comprising a central nervous system-active drug linked to glucuronic acid or glucosamine through an amide bond and uses thereof |
| 07/14/2005 | US20050153927 Gene expression inhibition; drug screening; peroxisome proliferator-activated receptor agonists such as fenofibrate |
| 07/14/2005 | US20050153920 Ribozymes used as prodrugs |
| 07/14/2005 | US20050153917 Gene overexpression/underexpression; antibodies; drug screening; kits |
| 07/14/2005 | US20050153912 Antiviral oligonucleotides targeting viral families |
| 07/14/2005 | US20050153908 Using a 1,2,4-triazole compound; mixture with viricide |
| 07/14/2005 | US20050153907 Use of ribofuranose derivatives against inflammatory bowel diseases |
| 07/14/2005 | US20050153906 Such as Hurler syndrome and Batten by administering an aminoglycosidesuch as gentamicin, G418, hygromycin B, paromomycin, tobramycin, lividomycin A, amikacin, sisomycin, or neomycin, optionally in combination with an enzyme effective for enzyme replacement therapy, a polyionic compound or gene therapy |
| 07/14/2005 | US20050153905 antibacterial activity in humans and mammals; semi-synthetic |